3Kouloulias EV, Kouvaris RJ ,Anpytas C,et al. An intra-patient doses-cation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases: monitoring using image-processing techniques. Strahlenther Onkol, 2003,179(7) :471-479.
4Theriauh RL, Lipon A, Hortodajyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lyric bone lesions: a randomized, placebo-controlled trial. Protrocol 18 Aredia Breast Cancer Study Group. J Oncol, 1999,17(3) :846-854.
5Splinter TA. Caehexia and cancer: a clinician's view. Ann Oncal, 1992,3(8) :525-527.
10BOISSIER S,MAGNETTO S,FRAAPPART L,et al.Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices[J].Cancer Res,1997,57(18):3890-3894.
6Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[ J]. CA Cancer J Clin, 2013, 63(1) : 11-30.
7Sugie-Oya A, Takakura A, Takao-Kawabata R, et al. Comparison of treatment effects of teriparatide and the bisphosphanate riseonate in an aged, osteopenic, ovariectomized rat model under va- rious clinical conditions[J]. J Bone Miner Metab, 2014, 7(4) :1 -12.
8Russell RG. Bisphosphonates: The first 40 years [ J ]. Bone 2011, 49(1) : 2-19.
9Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events : A com- bined analysis of 3 pivotal, randomised, phase 3 trials[ J]. Eur J Cancer, 2012, 48( 16): 3082-3092.
10Tubiana-Hulin M, Beuzeboc P, Manriac L, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases [ J ]. Bulletin Du Cancer, 2001, 88(7): 701-707.
